Digest Network Come funziona
Network
/
Società
Mi
Non verificato

Mirum Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieMercato azionarioSalute

65 comunicati stampa

Guarda tutti i comunicati
05/03/2026
Industria
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
25/02/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
23/02/2026
Eventi
Web e Social Network
Salute
Farmaceutica
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
18/02/2026
Salute
Biotecnologia
Sanità
Scienza
Farmaceutica
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
11/02/2026
Biotecnologia
Farmaceutica
Salute
Finanza
Mercato azionario
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
05/02/2026
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
05/02/2026
HIV, AIDS e malattie autoimmuni
Biotecnologia
Farmaceutica
Salute
Industria
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
26/01/2026
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato azionario
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
12/01/2026
Biotecnologia
Farmaceutica
Salute
Mercato azionario
Finanza
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
12/01/2026
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Web e Social Network
Eventi
Industria
Pubblico Esercizio/Vendita al dettaglio
Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0